Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzydamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 1.00 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzydamine SCHEMBL26172 | 1.00 | HRH3 (1.00) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| Benzydamine SCHEMBL8078518 | 0.99 | HRH3 (0.97) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| Benzydamine SCHEMBL42644 | 0.99 | POLB (1.00) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| Benzydamine SCHEMBL42645 | 0.99 | POLB (1.00) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| Benzydamine SCHEMBL1648787 | 0.97 | HRH3 (0.95) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| SCHEMBL8018576 | 0.96 | KDM4E (0.93) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| SCHEMBL9917397 | 0.94 | DRD1 (0.88) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| SCHEMBL8810482 | 0.91 | HRH3 (0.84) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| Benzydamine SCHEMBL7135139 | 0.91 | HRH3 (0.83) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 | |
| Benzydamine SCHEMBL28223703 | 0.91 | HRH3 (0.83) | HRH3KDM4EGUCY1B2CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014065-A1 | PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF | Dewey Beauty LLC (US) | 2026-01-15 | — | — | US | claimed |
| US-12324801-B2 | Water soluble compositions comprising purified cannabinoids | CANOPY GROWTH CORPORATION (CA) | 2025-06-10 | — | — | US | claimed |
| EP-2804601-B1 | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases | BIOSUCCESS BIOTECH CO LTD (US) | 2025-04-02 | — | — | EP | claimed |
| EP-4308078-B1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-03-12 | — | — | EP | claimed |
| EP-4308078-A1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS Lohmann Therapie-Systeme AG (DE) | 2024-01-24 | — | — | EP | claimed |
| CN-114466313-B | Intercity travel sample expansion method based on mobile phone signaling data | 同济大学 | 2023-03-28 | — | — | CN | claimed |
| WO-2022195044-A1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-09-22 | — | — | WO | claimed |
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | claimed |
| EP-3003285-B1 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST TWO ACTIVE PHARMACEUTICAL INGREDIENTS IN THE ORAL CAVITY | MCNEIL AB (SE) | 2022-02-16 | — | — | EP | claimed |
| EP-4719358-A2 | ENCAPSULATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | The General Hospital Corporation (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2026041220-A1 | FRAGRANCES WITH NEW ODOR MIXTURES AND USE THEREOF IN PERFUMERY | SYMRISE AG (DE) | 2026-02-26 | — | — | WO | disclosed |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | disclosed |
| EP-4436546-B1 | APPLICATION AID FOR ORAL THIN FILM | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2026-01-21 | — | — | EP | disclosed |
| US-11273164-B2 | Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith | TA Pharma Pty Limited (AU) | 2022-03-15 | — | — | US | disclosed |
| WO-2022049414-A1 | NITAZOXANIDE FOR USE TO TREAT COVID-19 | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-03-10 | — | — | WO | disclosed |
| EP-3960784-A1 | AQUEOUS COATING COMPOSITION | Covestro (Netherlands) B.V. (NL) | 2022-03-02 | — | — | EP | disclosed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220039455-A1 | POUCHED PRODUCT WITH LIQUID FLAVOR COMPOSITION | NCP NEXTGEN A/S (DK) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | HRH3 1832/4885KDM4E 1000/4885GUCY1B2 511/4885 |
| US-20260014065-A1 | PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF | DHCR24, CNR2, DSG1 | HRH3 877/4885KDM4E 1884/4885GUCY1B2 2243/4885 |
| US-12324801-B2 | Water soluble compositions comprising purified cannabinoids | CNR2, CNR1, S100P | HRH3 2185/4885KDM4E 374/4885GUCY1B2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.